Dupont-Lucas et al identified predictors of response to infliximab therapy by pediatric patients with perianal Crohn's disease. These can help to identify a patient who may benefit from therapy. The authors are from multiple hospitals in France in the GETAID (Grupe d'Etude therapeutique des Affections Inflammatoires du Tube Digestif) pediatrique.